AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04559919 — intervention group
Intervention type: OTHER
Intervention: Demographics and psychosocial
Description: We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
Study NCT04559919 — intervention group
Intervention type: OTHER
Intervention: Health care
Description: We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
Study NCT04515927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: Biological: JS002 Administered by subcutaneous injection
Study NCT01699932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride+metformin (Amaryl M®) - HOE4900
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01224665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy
Study NCT04047641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given Intravenous
Study NCT04047641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given Intravenous
Study NCT04047641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given by mouth
Study NCT01224665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy
Study NCT01224665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic standard lymphadenectomy
Description: Patients undergo standard pelvic lymphadenectomy.
Study NCT01224665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic extended lymphadenectomy
Description: Patients undergo extended pelvic lymphadenectomy
Study NCT03388437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NI-NAVA
Description: Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation
Study NCT03388437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation
Study NCT02738216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Yoga
Description: As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
Study NCT02738216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother Baby Wellness
Description: This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
Study NCT01969864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRSA Video Intervention
Study NCT01969864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PI Video Intervention
Study NCT01969864 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CDC Health Website Intervention
Study NCT00570128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil HCl
Description: Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
Study NCT00570128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid formulation matched to active treatment for oral administration.
Study NCT02906917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart
Description: Administered subcutaneously (s.c. under the skin) once daily.
Study NCT02906917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered subcutaneously (s.c. under the skin) once daily.
Study NCT02906917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Administered subcutaneously (s.c. under the skin) once daily.
Study NCT03470116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Mac Grath
Description: Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
Study NCT03470116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscopy
Description: Patients of this group will benefit direct laryngoscopy for intubation after curarization
Study NCT02132624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous 3rd generation CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
Study NCT01613937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dulce Mother lifestyle training program
Description: 12 once weekly culturally tailored lifestyle management sessions
Study NCT02625337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Study NCT02625337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02625337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Study NCT02625337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT02625337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
Study NCT02625337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
Study NCT02625337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
Study NCT04095390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg
Study NCT03092453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mature dendritic cell (DC) vaccine
Description: Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
Study NCT03092453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 300mg/m^2
Description: administered prior to subject's first DC dose
Study NCT03092453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: administered 7-8 weeks after subject's last DC dose
Study NCT00878072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
Study NCT04095390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: 125mg
Study NCT04095390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg
Study NCT04095390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg
Study NCT03047044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimizing basal infusion (B.I)
Description: In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
Study NCT03047044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCA mode
Description: Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
Study NCT04008069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab 200 mg administered subcutaneously
Study NCT02625337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
Study NCT04008069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT00191646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity
Study NCT02488109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Calorie Refeeding
Study NCT02488109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Calorie Refeeding
Study NCT01738217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluobeam
Study NCT04394130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
Study NCT02336906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350
Description: Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
Study NCT02336906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constipation behavioral therapy
Description: Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
Study NCT02336906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study NCT02336906 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Urotherapy
Description: The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study NCT01524016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
Study NCT03414073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knotted floss technique
Description: The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
Study NCT03414073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional flossing technique
Description: The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure.
Study NCT03414073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Conventional Interdental Brushing
Description: The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
Study NCT01788709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preparation cleaning solution
Study NCT05040139 — intervention group
Intervention type: PROCEDURE
Intervention: Malone Procedure
Description: Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
Study NCT05040139 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous endoscopic caecostomy
Description: Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
Study NCT03974893 — intervention group
Intervention type: OTHER
Intervention: Vegetarian Diet
Description: Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
Study NCT03065231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraventricular Drain
Description: As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
Study NCT03065231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Drain
Study NCT06504121 — intervention group
Intervention type: DEVICE
Intervention: Septal Occluder Device
Description: Transcatheter PFO closure with any commercially available septal occluder device
Study NCT00721916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Study NCT00191646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity
Study NCT00721916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
Study NCT01360437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg/day
Study NCT01360437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice a day
Study NCT03755180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
Study NCT03755180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
Study NCT03755180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
Study NCT04348955 — intervention group
Intervention type: BEHAVIORAL
Intervention: Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
Description: Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)
Study NCT03258996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified vestibular incision subperiosteal tunnel access
Description: Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured.
Study NCT03258996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap
Description: Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area.
Study NCT03493633 — intervention group
Intervention type: DEVICE
Intervention: EzyGain
Description: Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks
Study NCT01909115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 IU of Vitamin D3
Description: 1000 IU of Vitamin D will be administered in capsule form, once daily.
Study NCT01909115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU of Vitamin D3
Description: 4000 IU of Vitamin D will be administered in capsule form, once daily.
Study NCT04021160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS)
Description: 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
Study NCT04021160 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.